Short answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an 8-K current report with the SEC on March 6, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Michele Farmer resigning as CAO effective March 21, 2026: voluntary departure, no severance, no disagreements with company.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Michele Farmer resigning as CAO effective March 21, 2026: voluntary departure, no severance, no disagreements with company
- CFO Jim Gibson absorbs principal accounting officer role with no additional compensation change
- Gibson has served as CFO only since 2025: relatively new in role before taking on expanded responsibilities
Item 7.01 · Regulation FD Disclosure
- Settlement with PGI ends patent litigation; PACB pays $8M in Q1 2026, then $5M/year in Q1 2027–2029 (total minimum $23M)
- 2027 payment increases by $1M if 2026 revenue ≥$165M, another $1M if ≥$180M: creating a revenue-linked contingent liability up to $25M total
- PACB receives worldwide, royalty-free, non-exclusive license to U.S. Patent No. 7,767,441 plus 5.5-year covenant not to sue, binding on PGI successors
- Covenant not to sue converts open-ended litigation risk into defined, time-bound protection: reduces uncertainty for PACB's long-read sequencing commercial ecosystem
- All mutual claims and counterclaims dismissed; damages releases cover pre-settlement period, eliminating retroactive exposure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K filings
Get the next PACB 8-K as it lands
Follow PACB for push alerts, or ask the research agent what this filing means.